Publication | Closed Access

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Psychoactive DrugPsychiatryFunctional SelectivityMedicineAnimal ModelsExperimental PharmacologyPharmacotherapyAddictive DisordersPharmacologyDrug Discovery